Levels of angiopoietins 1 and 2 in induced sputum supernatant in patients with COPD

Cytokine

Volumn 58, Issue 3, 2012, Pages 455-460

  Bessa, Vasiliki ^a   Loukides, Stelios ^a   Hillas, Georgios ^b   Delimpoura, Vasiliki ^a   Simoes, Davina ^a   Kontogianni, Konstantina ^a   Papiris, Spyros ^a   Kostikas, Konstantinos ^a   Alchanatis, Manos ^a   Bakakos, Petros ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Angiogenesis; Chronic obstructive pulmonary disease; Induced sputum; Inflammation

Indexed keywords

ALBUMIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE; GELATINASE A; INTERLEUKIN 8; TIOTROPIUM BROMIDE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AIRWAY REMODELING; AIRWAY VASCULAR PERMEABILITY INDEX; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY TRACT PARAMETERS; SPUTUM ANALYSIS; SPUTUM LEVEL; SUPERNATANT; UPREGULATION;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 84860350809     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.03.007     Document Type: Article

References (39)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
2. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001, 164:S28-38.
3. Knox A.J., Stocks J., Sutcliffe A. Angiogenesis and vascular endothelial growth factor in COPD. Thorax 2005, 60:88-89.
4. Kranenburg A.R., de Boer W.I., Alagappan V.K., Sterk P.J., Sharma H.S. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:106-113.
5. Papaioannou A.I., Kostikas K., Kollia P., Gourgoulianis K.I. Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. Respir Res 2006, 7:128.
6. Santos S., Peinado V.I., Ramirez J., Morales-Blanhir J., Bastos R., Roca J., et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:1250-1256.
7. Kasahara Y., Tuder R.M., Cool C.D., Lynch D.A., Flores S.C., Voelkel N.F. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001, 163:737-744.
8. Makinde T., Murphy R.F., Agrawal D.K. Immunomodulatory role of vascular endothelial growth factor and angiopoietin-1 in airway remodeling. Curr Mol Med 2006, 6:831-841.
9. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514.
10. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
11. Feistritzer C., Mosheimer B.A., Sturn D.H., Bijuklic K., Patsch J.R., Wiedermann C.J. Expression and function of the angiopoietin receptor Tie-2 in human eosinophils. J Allergy Clin Immunol 2004, 114:1077-1084.
12. Kanazawa H., Nomura S., Asai K. Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 2007, 131:1035-1041.
13. Kanazawa H., Asai K., Tochino Y., Kyoh S., Kodama T., Hirata K. Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients. Clin Exp Allergy 2009, 39:1330-1337.
14. Standardization of Spirometry, 1994 Update. American Thoracic Society, Am. J Crit Care Med 152 (1995) 1107-1136.
15. Kips J.C., Fahy J.V., Hargreave F.E., Ind P.W., in't Veen J.C. Methods for sputum induction and analysis of induced sputum: a method for assessing airway inflammation in asthma. Eur Respir J 1998, 26(Suppl.):9S-12S.
16. Kanazawa H., Nomura S., Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med 2004, 169:1125-1130.
17. Park K.J., Bergin C.J., Clausen J.L. Quantitation of emphysema with three-dimensional CT densitometry: comparison with two-dimensional analysis, visual emphysema scores, and pulmonary function test results. Radiology 1999, 211:541-547.
18. Boschetto P., Quintavalle S., Zeni E., Leprotti S., Potena A., Ballerin L., et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006, 61:1037-1042.
19. Pichiule P., Chavez J.C., LaManna J.C. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem 2004, 279:12171-12180.
20. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
21. Ribatti D., Vacca A., Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol 2000, 35:227-231.
22. Wen F.Q., Liu X., Manda W., Terasaki Y., Kobayashi T., Abe S., et al. TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol 2003, 111:1307-1318.
23. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
24. McDonald D.M. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001, 164:S39-45.
25. Linden M., Rasmussen J.B., Piitulainen E., Tunek A., Larson M., Tegner H., et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993, 148:1226-1232.
26. Thompson A.B., Daughton D., Robbins R.A., Ghafouri M.A., Oehlerking M., Rennard S.I. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989, 140:1527-1537.
27. Balbi B., Aufiero A., Pesci A., Oddera S., Zanon P., Rossi G.A., et al. Lower respiratory tract inflammation in chronic bronchitis. Evaluation by bronchoalveolar lavage and changes associated with treatment with immucytal, a biological response modifier. Chest 1994, 106:819-826.
28. Keatings V.M., Barnes P.J. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997, 155:449-453.
29. Lacoste J.Y., Bousquet J., Chanez P., Van Vyve T., Simony-Lafontaine J., Lequeu N., et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993, 92:537-548.
30. Saetta M., Di Stefano A., Maestrelli P., Turato G., Ruggieri M.P., Roggeri A., et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994, 150:1646-1652.
31. Nishishita T., Lin P.C. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem 2004, 91:584-593.
32. Wu L., Chau J., Young R.P., Pokorny V., Mills G.D., Hopkins R., et al. Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 2004, 59:126-129.
33. Baraldo S., Bazzan E., Zanin M.E., Turato G., Garbisa S., Maestrelli P., et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007, 132:1733-1740.
34. Ziora D., Dworniczak S., Kozielski J. Induced sputum metalloproteinases and their inhibitors in relation to exhaled nitrogen oxide and sputum nitric oxides and other inflammatory cytokines in patients with chronic obstructive pulmonary disease. J Physiol Pharmacol 2008, 59(Suppl):809-817.
35. Iurlaro M., Scatena M., Zhu W.H., Fogel E., Wieting S.L., Nicosia R.F. Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins. J Cell Sci 2003, 116:3635-3643.
36. Hoshino M., Takahashi M., Takai Y., Sim J., Aoike N. Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy 2001, 31:722-730.
37. Chetta A., Zanini A., Foresi A., Del Donno M., Castagnaro A., D'Ippolito R., et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003, 167:751-757.
38. Nomura S., Kanazawa H., Hirata K., Iwao H., Yoshikawa J. Relationship between vascular endothelial growth factor and angiopoietin-2 in asthmatics before and after inhaled beclomethasone therapy. J Asthma 2005, 42:141-146.
39. Cho Y.J., Ma J.E., Yun E.Y., Kim Y.E., Kim H.C., Lee J.D., et al. Serum angiopoietin-2 levels are elevated during acute exacerbations of COPD. Respirology 2011, 16:284-290.